NVAX - ノババックス (Novavax Inc.) ノババックス

 NVAXのチャート


 NVAXの企業情報

symbol NVAx
会社名 Novavax Inc. (ノババックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ノババックス(Novavax Inc.)は臨床段階のバイオ医薬品会社である。同社は組換えナノ粒子ワクチン及びアジュバントの発見・開発・商業化に焦点を当てる。同社は組換えワクチンセグメントの開発を通じて事業を行っている。同社は、組換えナノ粒子ワクチン技術を用いて、既知疾患及び新興疾患に対応するワクチン候補物質を製造する。同社の製品パイプラインは、呼吸器合胞体ウイルス(RSV)、季節性インフルエンザ、パンデミックインフルエンザおよびエボラウイルス(EBOV)の臨床開発におけるワクチン候補の感染症に焦点を当てる。同社の人用鉛アジュバントであるMatrix-Mは、パンデミックインフルエンザH7N9ワクチン候補のフェーズI / II臨床試験にある。また、第I相臨床試験でEBOVワクチン候補と併せてMatrix-Mを試験している。同社は中東呼吸器症候群(MERS)を含む感染性疾患で、前臨床段階の追加プログラムを開発している。   ノババックスは、臨床段階の米国バイオ医薬品企業。組換えナノ粒子ワクチンおよび抗原性補強剤の発見、開発、商業化に従事する。呼吸器合胞体ウイルス、季節性インフルエンザと新型インフルエンザのための臨床開発などの感染症に対象を当て遺伝子組み換えによるワクチンを開発する。   Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
本社所在地 20 Firstfield Road Garthersburg MD 20878 USA
代表者氏名 James Francis Young ジェームズ・フランシス・ヤング
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-268-2000
設立年月日 1987年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 347人
url www.novavax.com
nasdaq_url https://www.nasdaq.com/symbol/nvax
adr_tso
EBITDA EBITDA(百万ドル) -165.13200
終値(lastsale) 2.065
時価総額(marketcap) 790052064.935
時価総額 時価総額(百万ドル) 723.09850
売上高 売上高(百万ドル) 39.19000
企業価値(EV) 企業価値(EV)(百万ドル) 874.46250
当期純利益 当期純利益(百万ドル) -186.29300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novavax Inc. revenues increased 65% to $20.4M. Net loss increased 3% to $90.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 16% to $83.5M (expense) Labor_Related Expenses in R&D increase of 18% to $5.6M (expense).

 NVAXのテクニカル分析


 NVAXのニュース

   Vaccine Hopeful Novavax Could Be Worth a Shot | Markets Insider  2020/10/28 11:52:24 Markets Insider
Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.
   COVID-19 vaccine: Novavax delays Phase 3 testing in U.S.  2020/10/27 18:58:58 United Press International
Maryland-based biotech firm Novavax on Tuesday announced it's delayed the start of its Phase 3 testing of a potential COVID-19 in North America.
   Novavax delays U.S. trial of COVID-19 vaccine to November | Health  2020/10/27 18:18:31 Devdiscourse
Novavax in August said it will supply 60 million doses of its coronavirus vaccine to the UK from as early as the first quarter of 2021. The company is also preparing to deliver 100 million doses to the United States by January after it was awarded $1.6 billion for its potential vaccine, and has also signed supply agreements with Canada and Japan.
   Novavax Rallies On Phase 3 Coronavirus Study Updates, Imminent Phase 2 Readout  2020/10/27 14:51:54 Benzinga
Novavax, Inc. (NASDAQ: NVAX ) issued … Full story available on Benzinga.com
   Covid-19 vaccine: Novavax delays US clinical trials to November  2020/10/27 14:45:26 Livemint
Novavax also says that data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021.Early-stage data had showed the vaccine produced high levels of antibodies against the novel coronavirus
   Here Is Everything We Know About A COVID-19 Vaccine  2020/09/04 09:30:00 Zero Hedge
Here Is Everything We Know About A COVID-19 Vaccine Tyler Durden Fri, 09/04/2020 - 05:30 Under normal conditions, vaccines require as long as ten years of testing before they're approved by regulators, then it takes some more time for drug companies to produce and distribute the product to millions of patients around the world. Until very recently, the notion that the world could quickly develop and mass produce a vaccine for some new infectious disease within a matter of months seemed impossible. Of course, these aren't normal times. After unveiling the adenovirus-vector vaccine developed by the Gameleya Institute, Russian President Putin claimed that the vaccine was tested first on a small group of willing participants, including one of his own adult daughters. The implication was that traditional standards of medical ethics don't always apply during extreme situations. With vaccine news being the dominant story on Thursday , as investors around the world watched as the administration pushed the states to prepare to start distributing vaccine doses on an emergency basis come Nov. 1.
   Novavax coronavirus vaccine appears safe in early trials; J&J COVID jab prevents severe illness in hamsters  2020/09/04 03:18:00 Times Now
Novavax says its potential coronavirus vaccine appears safe and elicits immune response in early human trials. J&J Ad26 vaccine protects against COVID-19 severe clinical disease in hamsters.
   Coronavirus Latest: Thursday, September 3  2020/09/03 19:31:51 Yahoo Finance
On Thursday, Novavax published positive trial data, saying that its coronavirus vaccine candidate was ‘safe’ and ‘elected an immune response. This come as Sanofi and GlaxoSmithKline announced that they would start phase 1/2 of their adjuvanted vaccine. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
   Here's How Much Investing $1,000 In Novavax In 2010 Would Be Worth Today  2020/09/03 18:50:13 Benzinga
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Novavax’s Difficult Decade: One poor performer of the last decade was biotech stock Novavax, Inc. (NASDAQ: NVAX ). Novavax spent much of the past decade under the radar, but its potential role in developing a vaccine for the COVID-19 coronavirus has gotten Wall Street’s attention in 2020. Prior to 2020, Novavax’s first big run on Wall Street came in 2015 when the company received an $89 million grant from the Bill & Melinda Gates Foundation to develop a vaccine for human respiratory syncytial virus, or RSV. The stock skyrocketed in 2015 after the company reported encouraging Phase 2 … Full story available on Benzinga.com
   Positive results of Novavax COVID-19 vaccine published in major medical journal  2020/09/03 15:50:06 United Press International
Promising early-stage results for a potential COVID-19 vaccine from U.S. biotech firm Novavax have been published in a major peer-reviewed medical journal, an important phase in the approval process.
   5 Stock Gainers for Friday: VBI Vaccines, Moderna, Novavax  2020/07/17 20:23:27 The Street
Stocks trading higher Friday include VBI Vaccines, Moderna, Novavax, Dynavax Technologies, and Quidel.
   Trending Stock Market News Friday: Novavax, Ericsson, Boeing  2020/07/17 16:35:05 The Street
Novavax has gone from an afterthought to winning the biggest federal contract for a potential coronavirus vaccine.
   Thinking about buying stock in Applied DNA Sciences, Microvision, Virgin Galactic, Blink Charging, or Novavax?  2020/07/17 13:31:00 PR Newswire
NEW YORK, July 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, MVIS, SPCE, BLNK, and NVAX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The vaccine story that's got everyone hooked  2020/07/17 03:33:43 Economic Times India
By Katie Thomas and Megan TwoheyIn late February, as the coronavirus spread around the world, Dr. Richard Hatchett, head of an international nonprofit that gives money to vaccine developers, got on an important call to discuss vaccine candidates after his plane touched down at London’s Heathrow Airport.Executives from the Bill & Melinda Gates Foundation, which helped found and finance the nonprofit, were on the line, enthusiastic about Novavax, a small biotech company they thought had the potential to develop a vaccine against the virus — fast.Although the company, based in Gaithersburg, Maryland, had never brought a vaccine to market in its 33-year history, these experts were optimistic about its technology, which uses moth cells to pump out crucial molecules at a much faster rate than typical vaccines — a major advantage in a pandemic.Hatchett’s organization, the Coalition for Epidemic Preparedness Innovations, would go on to invest $388 million in the company’s coronavirus vaccine.
   How a Struggling Biotech Won $1.6 Billion to Make a Coronavirus Vaccine  2020/07/16 14:32:42 New York Times
Novavax just received the Trump administration’s largest vaccine contract. In the Maryland company’s 33-year history, it has never brought a vaccine to market.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノババックス NVAX Novavax Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)